Boston Biomedical Announces First Patient Dosed with Investigational Toll-like Receptor (TLR) 7 Agonist DSP-0509 in Phase 1 Trial of Patients with Advanced Solid Tumors Refractory to Standard Treatment
CAMBRIDGE, Mass., /PRNewswire/ -- Boston Biomedical, Inc., a leading developer of novel cancer therapeutics with the goal of significantly improving patient outcomes, today announced that it has initiated clinical trial activities for DSP-0509, an investigational Toll-like receptor (TLR) 7 agonist. DSP-0509 is hypothesized to induce cytokine production, activate cytotoxic T lymphocytes, and sustain the immune-mediated antitumor activity by induction of immune system memory cells. The phase 1, open-label, multicenter trial will evaluate the safety and pharmacokinetic profile of intravenously administered DSP-0509 in adult patients with advanced solid tumors that are refractory to standard treatment.
"The initiation of this trial represents an important milestone for Boston Biomedical and reinforces the depth of our oncology pipeline," said Patricia S. Andrews, Chief Executive Officer, Boston Biomedical, Inc. "We are looking forward to exploring the safety and activity of DSP-0509 and understanding more about its potential in treating cancer."
The trial is being conducted at sites in the United States. Additional information on this trial, including comprehensive inclusion and exclusion criteria, can be accessed at www.ClinicalTrials.gov (NCT03416335).
About Boston Biomedical, Inc.
Additional information about the company and its pipeline can be found at www.BostonBiomedical.com.
Disclaimer Regarding Forward-Looking Statements
View original content:http://www.prnewswire.com/news-releases/boston-biomedical-announces-first-patient-dosed-with-investigational-toll-like-receptor-tlr-7-agonist-dsp-0509-in-phase-1-trial-of-patients-with-advanced-solid-tumors-refractory-to-standard-treatment-300711729.html
SOURCE Boston Biomedical, Inc.